Gene therapies in canine models for Duchenne muscular dystrophy

Area of Science:

• Pre-clinical research
• Animal models
• Genetic therapy

Background:

• Duchenne muscular dystrophy (DMD) therapies require rigorous pre-clinical testing in animal models for safety and efficacy.
• Murine and canine models are genetically homologous to DMD, serving as primary choices for pre-clinical studies.
• Canine models exhibit disease progression more analogous to human DMD patients than murine models, particularly in clinical and immunological aspects.

Purpose of the Study:

• To review the utility of canine models for Duchenne muscular dystrophy (DMD) in pre-clinical genetic therapy research.
• To highlight the advantages of canine models in predicting treatment responses at genetic, phenotypic, and immunological levels.
• To discuss the application of canine models in evaluating specific genetic therapeutic strategies for DMD.

Main Methods:

• Review of existing literature on Duchenne muscular dystrophy (DMD) animal models.
• Comparative analysis of murine and canine models for DMD pre-clinical studies.
• Focus on genetic therapy approaches including gene replacement, exon skipping, and gene editing within canine models.

Main Results:

• Canine models demonstrate closer clinical and immunological parallels to human Duchenne muscular dystrophy (DMD) progression than murine models.
• Evaluating genetic therapies in canine models may provide more reliable predictions of efficacy and safety.
• Canine models are suitable for assessing gene replacement, exon skipping, and gene editing strategies for DMD.

Conclusions:

• Canine models are valuable tools for advancing Duchenne muscular dystrophy (DMD) genetic therapy research.
• Their use can enhance the predictive power of pre-clinical studies, potentially accelerating the development of effective DMD treatments.
• Further research utilizing canine models is recommended for optimizing genetic therapies for Duchenne muscular dystrophy.